A biomedical breakthrough

A biomedical breakthrough

5 June 2017

Monash Janssen collaboration
Victorian Minister for Small Business, Innovation and Trade, Philip Dalidakis MP, Dr Dan Baker, Vice President, Immunology, Janssen R&D, Vice-Chancellor Professor Margaret Gardner AO, ARC Laureate Fellow Professor Jamie Rossjohn, Monash BDI, Dr Anish Suri, Senior Director, Immunology, Janssen R&D, Professor John Carroll, Director Monash BDI.

The multi-year partnership between the Biomedicine Discovery Institute (BDI) and Janssen Biotech, Inc – one of the Janssen Pharmaceutical companies of Johnson & Johnson – adds to Monash’s rising reputation in biomedical innovation.

Led by ARC Laureate Fellow, Professor Jamie Rossjohn, the group’s research investigates the impact of therapeutics on immune systems affected by rheumatoid arthritis. 

With almost 25 million sufferers of the debilitating disease worldwide, the agreement is the latest in a string of discoveries by BDI that has attracted early industry engagement, a growing priority for the University.

This collaboration is a great opportunity to take our advances in basic biomedical science and translate them to the market for the betterment of the Australian population and worldwide.